2. Signaling Pathways
  3. Anti-infection
  4. SARS-CoV

SARS-CoV

SARS coronavirus

SARS-CoV

Related Products

PDF 0.94 MB

SARS-CoV is the coronavirus (CoV) that causes severe acute respiratory syndrome (SARS). CoVs are enveloped viruses with a positive-sense, single-stranded RNA and can cause health-threatening outbreaks by targeting human respiratory system, including not only SARS, but also Middle East respiratory syndrome (MERS) and SARS-CoV-2 (the cause of COVID-19).

CoVs have four main structural proteins: spike(S), membrane (M), envelope (E), and nucleocapsid (N) proteins. An S protein mediates the CoV entry into host cells by attaching to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), followed by fusion between virus and host cell membranes. Genome replication and subgenomic RNA transcription after entry carry on with the participation of many nonstructural proteins such as Mpro (main protease or 3CLpro), PLpro (papain-like protease) and RdRp (RNA-dependent RNA polymerase). Then the structural proteins are translated, assembled into mature virions, and released via vesicles by exocytosis. It is worth mentioning that a protease called TMPRSS2 (transmembrane protease, serine 2) play important roles throughout the whole life of CoVs (such as attachment, assembling and release) by cleaving S protein. All the proteins and subcellular structures participated in the life cycle of CoVs are promising targets for treatment of disease caused by CoVs.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-182425
    MI-23
    		Inhibitor
    MI-23 is a SARS-CoV-2 main protease (SARS-CoV-2 Mpro) inhibitor with an IC50 of 7.6 nM. MI-23 is applicable to the research of COVID-19.
    MI-23
  • HY-135853R
    Molnupiravir (Standard)
    		Inhibitor
    Molnupiravir (Standard) is the analytical standard of Molnupiravir. This product is intended for research and analytical applications. Molnupiravir (EIDD-2801) is an orally bioavailable proagent of the ribonucleoside analog EIDD-1931. Molnupiravir has broad spectrum antiviral activity against influenza virus and multiple coronaviruses, such as SARS-CoV-2, MERS-CoV, SARS-CoV. Molnupiravir has the potential for the research of COVID-19, and seasonal and pandemic influenza.
    Molnupiravir (Standard)
  • HY-160943A
    F594-1001 hydrochloride
    		Inhibitor
    F594-1001 (compound 6) hydrochloride is a potent and highly selective SARS-CoV-2 Mac1-ADP-ribose inhibitor with IC50s of 8.5 μM, 68 μM and 45 μM for SARS-CoV-2 in AS, FP, and FRET assays, respectively. F594-1001 hydrochloride directly binds to SARS-CoV-2 Mac1 and exhibits a dose-dependent inhibition of Mac1 ADP-ribosylhydrolase activity.
    F594-1001 hydrochloride
  • HY-175829
    SARS-CoV-2-IN-119
    		Inhibitor
    SARS-CoV-2-IN-119 (Compound A28) is a SARS-CoV-2 fusion inhibitor. SARS-CoV-2-IN-119 strongly inhibits Omicron entry with an EC50s of 1.95  and 1.08 μM for pOmicron (BA.2.86.1) and wild Omicron. SARS-CoV-2-IN-119 also has antiviral activities against wild SARS-CoV-2 and other variants, such as pseudotyped Delta SARS-CoV-2, pOmicron (BA.4) and (KP.3). SARS-CoV-2-IN-119 directly interferes with Omicron S2-mediated viral membrane fusion to block Omicron virus into host cells. SARS-CoV-2-IN-119 can be used for COVID-19 research.
    SARS-CoV-2-IN-119
  • HY-158763
    MPI8
    		Inhibitor
    MPI8 (TG0205221) is an inhibitor of the major protease of SARS-CoV-2 (MPro) with high antiviral activity. MPI8 exerts its antiviral effect by dual and selective inhibition of SARS-CoV-2 MPro and host cell cysteine protease L (cathepsin L). MPI8 can be used in clinical studies of COVID-19.
    MPI8
  • HY-181927
    SARS-CoV-2 PLpro-IN-7
    		Inhibitor
    SARS-CoV-2 PLpro-IN-7 (Compound 18) is a selective SARS-CoV-2 PLpro inhibitor with an IC50 of 13.3 μM. SARS-CoV-2 PLpro-IN-7 exerts antiviral activity against SARS-CoV-2 (with an EC50 of 11 μM for SARS-CoV-2 in Huh7.5 cells). SARS-CoV-2 PLpro-IN-7 is applicable to research related to COVID-19.
    SARS-CoV-2 PLpro-IN-7
  • HY-B1607R
    Chlorphenoxamine (Standard)
    		Inhibitor
    Chlorphenoxamine (Standard) is the analytical standard of Chlorphenoxamine (HY-B1607). This product is intended for research and analytical applications. Chlorphenoxamine, an antihistamine and anticholinergic agent is a GPCR antagonist. Chlorphenoxamine inhibits multiple lethal viral diseases, such as SARS-CoV, MERS-CoV, EBOV and malaria. Chlorphenoxamine shows anti-filovirus activity against both EBOV and Marburg virus (MARV) with IC50s of 1.1 μM and 6.2 μM, respectively. Chlorphenoxamine is used for allergic conditions, urticaria, viral diseases and Parkinson’s disease.
    Chlorphenoxamine (Standard)
  • HY-P991763
    Anti-SARS-CoV-2 S protein (RBD) Antibody (SARS2-38)
    		Inhibitor
    Anti-SARS-CoV-2 S protein (RBD) Antibody (SARS2-38) reacts with many variants of SARS-CoV-2 that binds a conserved epitope on the RBD (amino acids K444 and G446). Anti-SARS-CoV-2 S protein (RBD) Antibody (SARS2-38) does not cross-react with the SARS-CoV-1 spike protein. Recommend Isotype Controls: Mouse IgG1 kappa, Isotype Control (HY-P99977).
    Anti-SARS-CoV-2 S protein (RBD) Antibody (SARS2-38)
  • HY-100211R
    TAPI-2 (Standard)
    		Inhibitor
    TAPI-2 (Standard) is the analytical standard of TAPI-2 (HY-100211). This product is intended for research and analytical applications. TAPI-2 (TNF Protease Inhibitor 2) is a broad-spectrum inhibitor of matrix metalloprotease (MMP), tumour necrosis factorα-converting enzyme (TACE) and a disintegrin and metalloproteinase (ADAM), with an IC50 of 20 μM for MMP. TAPI-2 blocks the entry of infectious SARS-CoV.
    TAPI-2 (Standard)
  • HY-160943
    F594-1001
    		Inhibitor
    F594-1001 (compound 6) is a potent and highly selective SARS-CoV-2 Mac1-ADP-ribose inhibitor with IC50s of 8.5 μM, 68 μM and 45 μM for SARS-CoV-2 in AS, FP, and FRET assays, respectively. F594-1001 directly binds to SARS-CoV-2 Mac1 and exhibits a dose-dependent inhibition of Mac1 ADP-ribosylhydrolase activity.
    F594-1001
  • HY-168584
    SARS-CoV-2-IN-102
    		Inhibitor
    SARS-CoV-2-IN-102 (example 58) is a SARS-CoV papain-like protease (PLpro) inhibitor with an IC50 <100 nM.
    SARS-CoV-2-IN-102
  • HY-181262
    SARS-CoV-2 PLpro-IN-4
    		Inhibitor
    SARS-CoV-2 PLpro-IN-4 is a SARS-CoV-2 papain-like protease (PLPro) inhibitor with an IC50 of 0.4 μM. SARS-CoV-2 PLpro-IN-4 binds to the S3 and S4 pockets of SARS-CoV-2 PLPro, thereby functionally inhibiting its activity. SARS-CoV-2 PLpro-IN-4 exhibits antiviral activity and can be used in research on COVID-19.
    SARS-CoV-2 PLpro-IN-4
  • HY-10237R
    Boceprevir (Standard)
    		Inhibitor
    Boceprevir (Standard) is the analytical standard of Boceprevir. This product is intended for research and analytical applications. Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with a Ki of 14 nM in both enzyme assay and an EC90 of 350 nM in cell-based replicon assay. Boceprevir inhibits SARS-CoV-2 3CLpro activity.
    Boceprevir (Standard)
  • HY-14909R
    Bardoxolone (Standard)
    		Inhibitor
    Bardoxolone (Standard) is the analytical standard of Bardoxolone (HY-14909). This product is intended for research and analytical applications. Bardoxolone is an orally active activator of nuclear regulatory factor (NRf-2) and an inhibitor of SARS-CoV-2 3CL protease. Bardoxolone inhibits SARS-CoV-2 3CL protease with an EC50 value of 0.43 μM in vero cells. Bardoxolone also inhibits necroptosis in HT-29 cells with an EC50 value of 1.30 μM by blocking necrosome formation through inhibiting phosphorylation of RIPK1 and RIPK3. Bardoxolone can be used in research on COVID-19, TNF-induced systemic inflammatory response syndrome (SIRS), and cerebral ischemia-reperfusion injury.
    Bardoxolone (Standard)
  • HY-100442S
    Paquinimod-d5
    		Inhibitor
    Paquinimod-d5 is a deuterated analog of Paquinimod (HY-100442). Paquinimod (ABR 215757) is a specific and orally active inhibitor of S100A8/S100A9. Paquinimod rescues the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice.
    Paquinimod-d<sub>5</sub>
  • HY-183661
    SCHEMBL12616233
    		Inhibitor
    SCHEMBL12616233 is a SARS-CoV-2 main protease (MPro) inhibitor. SCHEMBL12616233 binds to the active cavity of SARS-CoV-2 MPro and forms a stable complex. SCHEMBL12616233 can be used for the research of covid-19.
    SCHEMBL12616233
  • HY-123185
    (Rac)-Z-FA-FMK
    		Inhibitor
    (Rac)-Z-FA-FMK is the racemate of Z-FA-FMK. (Rac)-Z-FA-FMK is an inhibitor of cathepsin B with a Ki of 1.5 μM. (Rac)-Z-FA-FMK inhibits caspase-2, -3, -6, -7, and -9 with IC50s of 6.147, 15.41, 32.45, 9.077, and 110.7 μM. (Rac)-Z-FA-FMK inhibits the main protease of SARS-CoV-2 replication with an IC50 of 11.39 μM. (Rac)-Z-FA-FMK inhibits the increased IL-1β level induced by LPS and NF-κB transactivation in macrophages.
    (Rac)-Z-FA-FMK
  • HY-100575R
    Acriflavine (Standard)
    		Inhibitor
    Acriflavine (Standard) is the analytical standard of Acriflavine (HY-100575). This product is intended for research and analytical applications. Acriflavine (Acriflavinium chloride) is a fluorescent acridine dye that can be used to label nucleic acid. Acriflavine is an antiseptic agent. Acriflavine is a potent HIF-1 inhibitor that prevents the dimerization of HIF-1α and HIF-1β subunits. Acriflavine inhibits the interaction between monocarboxylate transporter 4 (MCT4) and Basigin. Acriflavine is used in cancer research, such as breast cancer, brain tumor and chronic myeloid leukemia. Acriflavine is a potent papain-like protease (PLpro) inhibitor, which inhibits SARS-CoV-2.
    Acriflavine (Standard)
  • HY-176229
    Mpro/Cathepsin L-IN-2
    		Inhibitor
    Mpro/Cathepsin L-IN-2 (Compound 1) is a dual irreversible inhibitor of SARS-CoV-2 main protease (Mpro, pIC50=8.61) and human cathepsin L (hCTSL, pIC50=7.64). Mpro/Cathepsin L-IN-2 is promising for research of COVID-19 and other coronavirus infections.
    Mpro/Cathepsin L-IN-2
  • HY-17367R
    Atazanavir (Standard)
    		Inhibitor
    Atazanavir (Standard) is the analytical standard of Atazanavir. This product is intended for research and analytical applications. Atazanavir (BMS-232632) is a highly selective and orally active HIV-1 protease inhibitor . Atazanavir is a substrate and inhibitor of CYP3A4, and an inhibitor of P-glycoprotein (P-gp). Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM. Atazanavir inhibits cardiac fibrosis, hyperlipidemia and induces malignant glioma death.
    Atazanavir (Standard)
Cat. No. Product Name / Synonyms Species Source